Dae Trades @DaeTrades - Twitter Profile

3 days ago

Yesterday was my worst day trading EVER! ...ended -5K. Just about shook me into hiatus. But with 276 left in the account I'm Gonna shake back!

1

0

6

DaeTrades retweeted

Old Media

@oldmedia

11 days ago

53

13K

2K

607

137K

DaeTrades retweeted

Massimo

@Rainmaker1973

14 days ago

Cannabis is no longer classified in the same category as heroin and LSD. After 55 years, the federal government has reclassified state-licensed medical marijuana and certain FDA-approved cannabis products from Schedule I to Schedule III. This represents one of the most significant shifts in U.S. cannabis policy in decades. Since 1970, marijuana had been listed as a Schedule I substance, a designation reserved for drugs regarded as having a high potential for abuse and no accepted medical use. Heroin and LSD continue to fall into that category. The old classification had grown increasingly at odds with real-world conditions. Forty states now maintain medical marijuana programs, and millions of Americans legally obtain cannabis products under state law. Researchers, physicians, and lawmakers have long maintained that equating regulated medical marijuana with heroin failed to reflect the available scientific evidence. The reclassification does not render marijuana legal under federal law. Recreational and other unlicensed forms of marijuana remain Schedule I substances. Interstate commerce is still restricted, and medical marijuana businesses must continue to comply with both state and federal registration rules. Nevertheless, the change carries substantial practical effects. State-licensed medical marijuana businesses are no longer bound by a federal tax provision that barred Schedule I and II drug operations from deducting ordinary business expenses. Researchers will also gain access to products from federally registered, state-licensed suppliers, enabling studies of cannabis formulations that more closely match those actually used by patients. Scientists continue to examine both the benefits and risks of marijuana. Existing evidence indicates potential value in treating chronic pain, chemotherapy-induced nausea, and appetite loss linked to certain medical conditions. At the same time, other studies have highlighted concerns regarding dependence, impaired driving, heavy use, and possible impacts on developing brains. Supporters view the reclassification as a long-overdue acknowledgment of marijuana’s medical applications. Critics caution that it may understate the genuine risks associated with frequent or underage consumption. The federal government has not legalized cannabis overall. For the first time since 1970, however, federally recognized medical marijuana is no longer treated as a substance lacking any accepted medical purpose.